## Recursion Pharmaceuticals Sees Notable Shift in Analyst Conviction and Institutional Backing
Recursion Pharmaceuticals (RXRX) is gaining traction among market participants as fresh analyst assessments point to stronger growth prospects. The consensus one-year price target has climbed to $7.14 per share, marking a 10.53% upward revision from the previous consensus of $6.46 recorded on December 3, 2025. This adjustment reflects growing confidence, with individual analyst forecasts spanning a broad range from $3.03 to $11.55 per share—suggesting the stock could appreciate 67.61% from its curre
Recursion Pharmaceuticals (RXRX) is gaining traction among market participants as fresh analyst assessments point to stronger growth prospects. The consensus one-year price target has climbed to $7.14 per share, marking a 10.53% upward revision from the previous consensus of $6.46 recorded on December 3, 2025. This adjustment reflects growing confidence, with individual analyst forecasts spanning a broad range from $3.03 to $11.55 per share—suggesting the stock could appreciate 67.61% from its curre